Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

PURPOSE: The survival benefit with adjuvant chemotherapy for patients with resected stage II-III non–small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive biomarkers in these patients have not yielded clinically useful tests. We report findings from the Lung Adjuvant...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Devarakonda, Siddhartha, Rotolo, Federico, Tsao, Ming-Sound, Lanc, Irena, Brambilla, Elisabeth, Masood, Ashiq, Olaussen, Ken A., Fulton, Robert, Sakashita, Shingo, McLeer-Florin, Anne, Ding, Keyue, Le Teuff, Gwénaël, Shepherd, Frances A., Pignon, Jean-Pierre, Graziano, Stephen L., Kratzke, Robert, Soria, Jean-Charles, Seymour, Lesley, Govindan, Ramaswamy, Michiels, Stefan
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2018
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804865/
https://ncbi.nlm.nih.gov/pubmed/30106638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.78.1963
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items